Publication Date:
2018
Short description:
Espay, A. J., Morgante, F., Merola, A., Fasano, A., Marsili, L., Fox, S. H., Bezard, E., Picconi, B., Calabresi, P., Lang, A. E., Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts, <>, 2018; 84 (6): 797-811. [doi:10.1002/ana.25364] [http://hdl.handle.net/10807/170670]
abstract:
Levodopa-induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa-to-dopamine conversion in serotonergic neurons, hyperactivity of corticostriatal glutamatergic transmission, and overstimulation of nicotinic acetylcholine receptors on dopamine-releasing axons. Delay in initiating levodopa is no longer recommended, as dyskinesia development is a function of disease duration rather than cumulative levodopa exposure. We review current and in-development treatments for peak-dose dyskinesia but suggest that improvements in levodopa delivery alone may reduce its future prevalence. Ann Neurol 2018;84:797–811.
Iris type:
Articolo in rivista, Nota a sentenza
Keywords:
Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Dyskinesia, Drug-Induced
List of contributors:
Espay, A. J.; Morgante, F.; Merola, Annamaria; Fasano, Alfonso; Marsili, L.; Fox, S. H.; Bezard, E.; Picconi, B.; Calabresi, Paolo; Lang, A. E.
Published in: